

Pol Specenier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3576031/publications.pdf>

Version: 2024-02-01

104
papers

3,838
citations

279798

23
h-index

128289

60
g-index

108
all docs

108
docs citations

108
times ranked

5899
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 393, 156-167.	13.7	1,153
2	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 583-594.	10.7	358
3	Optimal treatment for recurrent/metastatic head and neck cancer. <i>Annals of Oncology</i> , 2010, 21, vii252-vii261.	1.2	286
4	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156.	1.2	197
5	Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3144-3154.	3.6	156
6	A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy. <i>Oncologist</i> , 2010, 15, 699-731.	3.7	137
7	Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	1.6	100
8	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. <i>Oncologist</i> , 2013, 18, 850-864.	3.7	82
9	Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. <i>Medicinal Research Reviews</i> , 2016, 36, 749-786.	10.5	78
10	Current concepts for the management of head and neck cancer: Chemotherapy. <i>Oral Oncology</i> , 2009, 45, 409-415.	1.5	75
11	Cetuximab: its unique place in head and neck cancer treatment. <i>Biologics: Targets and Therapy</i> , 2013, 7, 77.	3.2	62
12	Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. <i>Cancer Letters</i> , 2014, 354, 365-377.	7.2	53
13	Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. <i>Annals of Oncology</i> , 2018, 29, 1987-1994.	1.2	52
14	Cetuximab in the treatment of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 511-524.	2.4	40
15	Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 901-915.	2.4	40
16	Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited?. <i>Cancer Letters</i> , 2007, 256, 166-177.	7.2	39
17	Recurrent head and neck cancer: current treatment and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 375-391.	2.4	39
18	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. <i>BMC Research Notes</i> , 2014, 7, 337.	1.4	35

#	ARTICLE	IF	CITATIONS
19	Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3803-3811.	4.1	34
20	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	2.8	33
21	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	4.1	32
22	A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 13-20.	2.3	30
23	Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. <i>Annals of Oncology</i> , 2007, 18, 961-962.	1.2	26
24	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 811-826.	2.4	26
25	A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 60-70.	3.3	26
26	Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?. <i>Trials</i> , 2015, 16, 395.	1.6	23
27	Quality of life in oropharyngeal cancer: a structured review of the literature. <i>Supportive Care in Cancer</i> , 2018, 26, 2511-2518.	2.2	23
28	Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. <i>Quality of Life Research</i> , 2019, 28, 663-676.	3.1	23
29	Advances in the systemic treatment of head and neck cancers. <i>Current Opinion in Oncology</i> , 2010, 22, 200-205.	2.4	22
30	JESSICA: an object-oriented hypermedia publishing processor. <i>Computer Networks</i> , 1998, 30, 281-290.	1.0	20
31	Nivolumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1247-1261.	2.4	20
32	Health related quality of life in older patients with solid tumors and prognostic factors for decline. <i>Journal of Geriatric Oncology</i> , 2019, 10, 895-903.	1.0	20
33	Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapy (PRESTO trial). <i>Trials</i> , 2020, 21, 237.	1.6	20
34	Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 472-477.	1.3	19
35	Bevacizumab in glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 9-18.	2.4	19
36	A phase I study of volasertib combined with afatinib, in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 843-851.	2.3	19

#	ARTICLE	IF	CITATIONS
37	A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms. <i>Frontiers in Oncology</i> , 2020, 10, 1020.	2.8	19
38	Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. <i>American Journal of Cancer Research</i> , 2015, 5, 1921-38.	1.4	19
39	Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 233-241.	2.3	18
40	TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. <i>Annals of Oncology</i> , 2017, 28, 2219-2224.	1.2	18
41	The role of taxanes and targeted therapies in locally advanced head and neck cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 195-201.	2.4	17
42	Biologic Therapy in Head and Neck Cancer: A Road with Hurdles. <i>ISRN Oncology</i> , 2012, 2012, 1-15.	2.1	17
43	<i>In Vitro</i> study of the Polo-like kinase 1 inhibitor volasertib in non-small cell lung cancer reveals a role for the tumor suppressor p53. <i>Molecular Oncology</i> , 2019, 13, 1196-1213.	4.6	17
44	Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemo-naïve patients with squamous cell carcinoma of the head and neck: long-term follow up data. <i>Annals of Oncology</i> , 2007, 18, 1856-1860.	1.2	16
45	Expression Analysis on Archival Material. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 203-211.	2.1	16
46	EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2012, 105, 238-240.	0.6	16
47	Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. <i>Oncologist</i> , 2016, 21, 59-71.	3.7	16
48	Targeted therapies in head and neck cancer. <i>Targeted Oncology</i> , 2007, 2, 73-88.	3.6	15
49	Afatinib in squamous cell carcinoma of the head and neck. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1295-1301.	1.8	15
50	Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients. <i>Head and Neck</i> , 2019, 41, 2197-2207.	2.0	14
51	Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 368-374.	1.0	14
52	Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 18.	3.0	11
53	Treatment of intractable hiccup in a terminal cancer patient with nebulized saline. <i>Palliative Medicine</i> , 1996, 10, 166-167.	3.1	10
54	Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. <i>Journal of Neurology</i> , 2015, 262, 742-751.	3.6	10

#	ARTICLE	IF	CITATIONS
55	Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 3417-3423.	2.2	10
56	Pembrolizumab use for the treatment of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 765-780.	3.1	10
57	Nivolumab in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 409-420.	2.4	9
58	Sequential treatment with vindesineâ€“ifosfamideâ€“platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: A phase II trial1Data presented in part at the 61st Annual International Scientific Assembly of the American College of Chest Physicians, New York, NY, USA, 31 October 1995.1. <i>Lung Cancer</i> , 1998, 22, 45-53.	2.0	8
59	Antineoplastic therapy-induced pulmonary toxicity. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 997-1006.	2.4	8
60	An overview of binimetinib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 747-754.	1.8	8
61	A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck. <i>BMC Cancer</i> , 2009, 9, 273.	2.6	7
62	Efficacy of nab-paclitaxel in treating metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 495-500.	1.8	7
63	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. <i>Cancers</i> , 2019, 11, 1893.	3.7	7
64	The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (â‰¥70ÂŸyears) patients with different cancer tumors. <i>Journal of Geriatric Oncology</i> , 2020, 11, 926-936.	1.0	7
65	Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021, 29, 168-177.	1.8	7
66	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1511-1521.	2.4	6
67	Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1629-1636.	1.6	6
68	ACUTE HEMIPLEGIA CAUSED BY A RETROGRADE CEREBRAL VENOUS AIR EMBOLISM AFTER CENTRAL VENOUS CATHETER REMOVAL: AN ILLUSTRATIVE CASE.. <i>Acta Clinica Belgica</i> , 2010, 65, 51-53.	1.2	5
69	The Economics of the Treatment and Follow-Up of Patients with Glioblastoma. <i>Value in Health</i> , 2015, 18, A448.	0.3	5
70	Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck. <i>Anticancer Research</i> , 2009, 29, 5137-42.	1.1	5
71	Locoregionally advanced squamous cell carcinoma of the head and neck: chemoradiation or bioradiation. <i>Translational Cancer Research</i> , 2016, 5, 223-228.	1.0	4
72	Phase 1B Study of Mehd7945A (Mehd) Plus Cisplatin/Fluorouracil (Cis/5Fu) or Carboplatin/Paclitaxel (Carbo/Pac) for 1St-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (Rmscchn). <i>Annals of Oncology</i> , 2014, 25, iv341.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Induction chemotherapy in head and neck cancer: are we too ambitious?. <i>Future Oncology</i> , 2014, 10, 337-340.	2.4	3
74	Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience. <i>Oncologist</i> , 2015, 20, 279-290.	3.7	3
75	Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 185-191.	2.3	2
76	Medical Cost Associated with Treatment and Follow-Up of Patients with Head and Neck Cancer. <i>Value in Health</i> , 2015, 18, A449.	0.3	2
77	Induction chemotherapy in squamous cell carcinoma of the head and neck: Saved by the bell?. <i>Oral Oncology</i> , 2015, 51, e5-e7.	1.5	2
78	The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89. <i>Acta Urologica Belgica</i> , 1996, 64, 13-9.	0.1	2
79	Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. <i>Anti-Cancer Drugs</i> , 2010, 21, 306-312.	1.4	1
80	Cost and Cost-Effectiveness Data on Pancreatic Cancer: a Comprehensive Review of the Literature. <i>Value in Health</i> , 2015, 18, A448-A449.	0.3	1
81	2817 12-year Follow-up (FU) Data and late local toxicity Of Two Cohorts of patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) treated with Concomitant Chemoradiation (CCRT) With Or Without Induction Chemotherapy (ICT). <i>European Journal of Cancer</i> , 2015, 51, S563.	2.8	1
82	The prognostic value of the comprehensive geriatric assessment (CGA) in elderly cancer patients (ECP) treated with chemotherapy (CT): a systematic review. <i>European Journal of Cancer</i> , 2017, 72, S164-S165.	2.8	1
83	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 13-28.	1.4	1
84	Targeted Therapy in Combination with Chemotherapy in Recurrent and/or Metastatic Head and Neck Cancer. <i>European Oncology and Haematology</i> , 2010, 06, 43.	0.0	1
85	CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation. <i>Annals of Translational Medicine</i> , 2016, 4, 432-432.	1.7	1
86	5536 POSTER A non-randomized single-centre comparison of induction chemotherapy followed by chemoradiation versus chemoradiation for locally-advanced squamous cell carcinoma of the head and neck. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 335.	2.2	0
87	O111. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology Supplement</i> , 2009, 3, 93.	0.0	0
88	PCN53 Real World Management and Costs in Metastatic Malignant Melanoma (MM) Patients: A Pilot Study Based on an Institutional Patient Registry. <i>Value in Health</i> , 2012, 15, A418.	0.3	0
89	Real World Management and Costs in Unresectable Metastatic Melanoma (MM) Patients: Update of a Pilot Study Based on an Institutional Patient Registry. <i>Value in Health</i> , 2013, 16, A403.	0.3	0
90	68 Can the P53 status predict the outcome of Polo-like kinase 1 inhibition in non-small cell lung cancer cell lines?. <i>European Journal of Cancer</i> , 2014, 50, 27.	2.8	0

#	ARTICLE	IF	CITATIONS
91	Real World Management and Costs in Unresectable Metastatic Melanoma (UMM) Patients Treated at the Antwerp University Hospital (UZA). Value in Health, 2014, 17, A627.	0.3	0
92	1560 Quality of life (QoL) evaluation in head and neck cancer (HNC) patients: Electronics beats paper. European Journal of Cancer, 2015, 51, S224.	2.8	0
93	2822 Gemcitabine-based chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: A literature review and meta-analysis. European Journal of Cancer, 2015, 51, S565-S566.	2.8	0
94	Atypical Carcinoid Tumor of the Larynx: A Challenging Diagnostic Case. , 2016, 6, .		0
95	Authorsâ€™ response letter: Quality of life in oropharyngeal cancer: a structured review of the literature. Supportive Care in Cancer, 2019, 27, 1583-1583.	2.2	0
96	A non-randomized single-center comparison of induction chemotherapy (IC) followed by chemoradiation (CRT) versus CRT for locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology, 2008, 26, 17004-17004.	1.6	0
97	Abstract 280: RNA isolation from formalin-fixed paraffin-embedded material: A comparison of five commercially available RNA isolation kits. , 2011, , .		0
98	Abstract 1898: Potential molecular mechanisms of intrinsic resistance to EGFR-targeting monoclonal antibodies in HNSCC. , 2012, , .		0
99	Abstract 1030: The intriguing interplay between EGFR inhibitors and the hypoxic microenvironment: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.. , 2013, , .		0
100	Abstract 5628: Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP6.. , 2013, , .		0
101	Minerva's comment was not evidence based. BMJ: British Medical Journal, 1996, 313, 113-113.	2.3	0
102	Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck. Current Clinical Pathology, 2015, , 81-87.	0.0	0
103	Abstract 258: Is P53 the up-and-coming predictive biomarker for volasertib treatment in NSCLC. , 2016, , .		0
104	Long-term recurrence-free survival after hepatic resection for metachronous gastric cancer liver metastases. Translational Cancer Research, 2016, 5, 497-499.	1.0	0